Thomas Strüngmann

Thomas Strüngmann (born 1950) founded generic drug maker Hexal AG ($1.6 billion sales during 2004) in 1986. In 2005, he and his brother Andreas sold Hexal for $6.7B.[1] They earned $8B on their stake in BioNTech SE, the German company developing the Pfizer–BioNTech COVID-19 vaccine.[2] They own approximately 50% of the company as well as significant ownership in 4SC and Immatics.[3] He currently has the largest health-care earned fortune with his brother. [4]

The brothers operate out of a family office, Athos Service. [1]

See also

References
  1. Manskar, Noah (2020-11-13). "COVID-19 vaccine hopes have made these twins $8 billion richer". New York Post. Retrieved 2021-07-13.
  2. Stupples, Benjamin (November 13, 2020). "Brothers Build $22 Billion Fortune on Hope for Covid-19 Vaccine". Bloomberg.
  3. Manskar, Noah (2020-11-13). "COVID-19 vaccine hopes have made these twins $8 billion richer". New York Post. Retrieved 2021-07-13.
  4. "Bloomberg Billionaires Index". Bloomberg.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.